Read this company snapshot
Daily valuation snapshot
ProMIS Neurosciences Inc. Common Shares (ON): source evidence dated 2026-10-09.
- Daily close (USD)
- $9.61
- Market capitalization (USD)
- $86,179,529.73
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.74
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PMN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PMN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing PMN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $9.61 |
| Market capitalization (USD) | $86,179,529.73 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.74 |
No matching rows. Clear the filter to see all records.
Read PMN's valuation metrics
Company size
ProMIS Neurosciences Inc. Common Shares (ON)'s recorded market capitalization is $86,179,529.73. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
PMN's recorded price-to-book ratio is 1.74. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research ProMIS Neurosciences Inc. Common Shares (ON) with Aurora
Use the snapshot above to ask a specific question about PMN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow PMN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.